A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 133 participants.

Also called NCT03338426

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 133 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03338426
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03338426. Randomized; triple masking; primary purpose treatment. Start 2018-01-15 (actual); primary completion 2019-04-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia
Acronym
FIESTA
Condition
Essential Hypertension, Dyslipidemia
Intervention (Drug)
Fimasartan 120mg
Intervention (Drug)
Atorvastatin 40mg
Intervention (Drug)
Placebo for Fimasartan 120mg
Intervention (Drug)
Placebo for Atorvastatin 40mg
Lead sponsor
Boryung Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct03338426
Content hash
17055054eb2c41cbcf06899d88b27f333a1c7ccee39a513e268e7048391a7324